163 related articles for article (PubMed ID: 38655266)
1. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
[TBL] [Abstract][Full Text] [Related]
2. Bulk RNA-seq and scRNA-seq reveal SLC7A11, a key regulatory molecule of ferroptosis, is a prognostic-related biomarker and highly related to the immune system in lung adenocarcinoma.
Wu X; Wang S; Chen K
Medicine (Baltimore); 2023 Sep; 102(37):e34876. PubMed ID: 37713821
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma.
Qian L; Wang F; Lu SM; Miao HJ; He X; Feng J; Huang H; Shi RF; Zhang JG
J Immunol Res; 2022; 2022():1951620. PubMed ID: 35509981
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract][Full Text] [Related]
5. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
Zhou M; Zhang X; Li T; Chen Y
J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
[TBL] [Abstract][Full Text] [Related]
7. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
9. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
10. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
11. FOXA1/UBE2T Inhibits CD8
Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
[TBL] [Abstract][Full Text] [Related]
12. Hsa_circ_0070440 promotes lung adenocarcinoma progression by SLC7A11-mediated-ferroptosis.
Zhao Y; Cui Q; Shen J; Shen W; Weng Y
Histol Histopathol; 2023 Dec; 38(12):1429-1441. PubMed ID: 36852950
[TBL] [Abstract][Full Text] [Related]
13. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
14. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
15. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
[TBL] [Abstract][Full Text] [Related]
16. Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma.
Zhang L; Jiang B; Lan Z; Yang C; Yao Y; Lin J; Wei Q
Front Immunol; 2022; 13():983570. PubMed ID: 36275753
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
18. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma.
Liang Y; Su S; Lun Z; Zhong Z; Yu W; He G; Wang Q; Wang J; Huang S
Front Mol Biosci; 2022; 9():1012505. PubMed ID: 36267158
[No Abstract] [Full Text] [Related]
20. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
